Oxandrolone for the Treatment of Bone Marrow Aplasia in Fanconi Anemia - Full Text View

Sponsored by:	FDA Office of Orphan Products Development
Information provided by:	FDA Office of Orphan Products Development
ClinicalTrials.gov Identifier:	NCT00243399

Purpose

The purpose of this study is to evaluate the safety of the drug oxandrolone (a type of androgen steroid) in patients with Fanconi anemia (FA), and to determine if this drug can help in the treatment of bone marrow failure in these patients. Androgen steroids are male hormones that can stimulate the production of red blood cells (the cells which carry oxygen in the blood) and platelets (cells that help blood clot).

Condition	Intervention	Phase
Fanconi Anemia	Drug: Oxandrolone	Phase I

MedlinePlus related topics: Anemia

Drug Information available for: Oxandrolone

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	A Pilot Trial of Oxandrolone for the Treatment of Bone Marrow Aplasia in Patients With Fanconi Anemia

Further study details as provided by FDA Office of Orphan Products Development:

Estimated Enrollment:

10

Detailed Description:

The primary purpose of this study is to evaluate the safety of the drug oxandrolone in patients with Fanconi anemia (FA), and secondarily to determine if this drug can help in the treatment of bone marrow failure in these patients. It is hoped that oxandrolone will have less side effects than oxymetholone, the androgen used most frequently in the short-term treatment of bone marrow failure in FA patients. Subjects will be enrolled for approximately 18 to 30 months (12 - 24 months of treatment and 6 months additional monitoring). The oxandrolone starting dose is 0.04mg/kg/day. Study monitoring includes weekly complete blood counts, monthly serum chemistry labs, quarterly physical examinations including virilization exams and liver ultrasounds. Semi-annually, hand radiographs are obtained for bone maturation and behavioral assessments are conducted to detect any aggressive behavior or mood changes. If no improvement n the subject’s blood counts are noted after 4 months of therapy, the dose will be increased to 0.08mg/kg/day for a period of 4 more months. If no improvement is noted after a total of eight months, oxandrolone will be discontinued. If the blood counts show improvement, then the drug will continue for a minimum of twelve months. Subjects may remain on study and receive a total of 24 months of therapy if they have a response in their blood counts without unacceptable side effects. Post-treatment monitoring includes blood work and ultrasound every three months, and hand radiograph at six months.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients must be diagnosed with Fanconi anemia that is documented by a positive test for increased chromosomal breakage with mitomycin C or diepoxybutane.
At least the following peripheral blood cytopenias: (without transfusion) Absolute neutrophil count < 500/mm3 or Platelet count < 30,000/mm3 or Hemoglobin < 8.0 gm/dl
Negative pregnancy test by hCG testing, if of child-bearing potential.
Agreement to use a medically approved form of birth control, if of child-bearing potential.
Signed informed consent by the patient or legally authorized representative.
Patients must be 14 kg.
Male patients will be included until the time of puberty. With the onset of puberty, they will be included until the testosterone levels reach 100 ng/dl at which time they will be excluded from the study.

Exclusion Criteria:

Malignancy
Concurrent enrollment in any other study using an investigational drug.
Concurrent use of anticoagulants.
Use of androgen therapy within last three months.
Patients with severe liver disease as defined by SGOT or SGPT greater than or equal to 2.5x the upper limit of normal or total bilirubin greater than or equal to 1.5x the upper limit of normal.
Patients with renal disease as defined by serum creatinine greater than or equal to 1.5 x the upper limit of normal for age.
Patients less than 14 kg.
Patients who have failed previous therapy with oxymetholone.

-

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00243399

Contacts

Contact: Moira Haren, M.S., PA-C	513-636-9972	moira.haren@cchmc.org
Contact: Robin Mueller, RN	513-636-3218

Locations

United States, Ohio
Cincinnati Children's Hospital Medical Center	Recruiting
Cincinnati, Ohio, United States, 45229-3039
Principal Investigator: Franklin O Smith, M.D.

Sponsors and Collaborators

FDA Office of Orphan Products Development

Investigators

Principal Investigator:

Franklin O Smith, M.D.

Children's Hospital Medical Center, Cincinnati

More Information

No publications provided

Study ID Numbers:	2539, FD-R-002539-01
Study First Received:	October 20, 2005
Last Updated:	October 26, 2005
ClinicalTrials.gov Identifier:	NCT00243399 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by FDA Office of Orphan Products Development:

Fanconi anemia
FA

Study placed in the following topic categories:

Metabolic Diseases
Hematologic Diseases
Aplastic Anemia
Hormone Antagonists
Fanconi Anemia
Hormones, Hormone Substitutes, and Hormone Antagonists
Anemia
Hormones

Fanconi's Anemia
Oxandrolone
Anabolic Agents
Genetic Diseases, Inborn
Anemia, Aplastic
Bone Marrow Diseases
Metabolic Disorder
Androgens

Additional relevant MeSH terms:

Metabolic Diseases
Hematologic Diseases
Fanconi Anemia
Physiological Effects of Drugs
DNA Repair-Deficiency Disorders
Anemia
Hormones, Hormone Substitutes, and Hormone Antagonists
Hormones

Pharmacologic Actions
Oxandrolone
Anabolic Agents
Anemia, Hypoplastic, Congenital
Genetic Diseases, Inborn
Anemia, Aplastic
Bone Marrow Diseases
Androgens

ClinicalTrials.gov processed this record on May 07, 2009